Cellebrite DI (NASDAQ:CLBT) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Cellebrite DI (NASDAQ:CLBT) had its target price upped by analysts at Needham & Company LLC from $22.00 to $24.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s target price would suggest a potential upside of 30.08% from the stock’s current price.

Other research analysts have also issued reports about the company. Lake Street Capital cut their target price on Cellebrite DI from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, August 15th. Wall Street Zen cut shares of Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, November 7th. Finally, JPMorgan Chase & Co. upped their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the company an “overweight” rating in a research note on Wednesday, September 24th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Cellebrite DI Price Performance

NASDAQ CLBT opened at $18.45 on Thursday. The company’s fifty day moving average is $17.81 and its two-hundred day moving average is $16.70. Cellebrite DI has a 52-week low of $13.10 and a 52-week high of $26.30. The firm has a market capitalization of $4.42 billion, a price-to-earnings ratio of -24.28, a P/E/G ratio of 3.16 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Wednesday, November 12th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). The firm had revenue of $126.03 million for the quarter, compared to analyst estimates of $122.98 million. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The firm’s quarterly revenue was up 17.9% compared to the same quarter last year. During the same period last year, the business earned $0.14 earnings per share. Cellebrite DI has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, sell-side analysts expect that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

Large investors have recently bought and sold shares of the business. Venturi Wealth Management LLC raised its position in Cellebrite DI by 5.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 14,700 shares of the company’s stock valued at $272,000 after purchasing an additional 700 shares during the last quarter. CWM LLC increased its stake in shares of Cellebrite DI by 85.7% in the third quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after buying an additional 720 shares in the last quarter. Signaturefd LLC raised its stake in shares of Cellebrite DI by 68.3% in the second quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock worth $32,000 after acquiring an additional 819 shares during the last quarter. Blue Trust Inc. lifted its position in shares of Cellebrite DI by 4.0% during the third quarter. Blue Trust Inc. now owns 23,121 shares of the company’s stock worth $428,000 after purchasing an additional 898 shares in the last quarter. Finally, SkyView Investment Advisors LLC increased its holdings in shares of Cellebrite DI by 2.6% in the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock valued at $597,000 after purchasing an additional 970 shares in the last quarter. 45.88% of the stock is currently owned by institutional investors.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.